SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00260520

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Low Molecular Weight Heparin Vs No Treatment in Pregnant Women With Previous Preeclampsia or Fetal Growth Restriction Who Were Heterozygote for Factor V Leiden or Prothrombin Gene G20210A Mutation

The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both.

NCT00260520 Preeclampsia
MeSH: Pre-Eclampsia Fetal Growth Retardation
HPO: Intrauterine growth retardation Preeclampsia Toxemia of pregnancy

1 Interventions

Name: Dalteparin

Type: Drug



There is one SNP

SNPs


1 G20210A

Low Molecular Weight Heparin Vs No Treatment in Pregnant Women With Previous Preeclampsia or Fetal Growth Restriction Who Were Heterozygote for Factor V Leiden or Prothrombin Gene G20210A Mutation. --- G20210A ---

LMWH to Prevent Preeclampsia and Fetal Growth Restriction The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both. --- G20210A ---

Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Preeclampsia Pre-Eclampsia Fetal Growth Retardation The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both. --- G20210A ---

Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Preeclampsia Pre-Eclampsia Fetal Growth Retardation The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both. --- G20210A --- --- G20210A ---

Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Preeclampsia Pre-Eclampsia Fetal Growth Retardation The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both. --- G20210A --- --- G20210A --- --- G20210A ---

Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Preeclampsia Pre-Eclampsia Fetal Growth Retardation The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both. --- G20210A --- --- G20210A --- --- G20210A --- --- G20210A ---

Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Preeclampsia Pre-Eclampsia Fetal Growth Retardation The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both. --- G20210A --- --- G20210A --- --- G20210A --- --- G20210A --- --- G20210A ---



HPO Nodes


HPO:
Intrauterine growth retardation
Genes 589
NUS1 GATAD2B LETM1 ARID1B GTF2H5 UBR1 ORC1 RTEL1 GFM2 NIPBL STRA6 CTC1 RBBP8 COQ2 LAGE3 COG4 TGIF1 CDON PHGDH SLC18A3 CDKN1C FAM111A GINS1 GCK INS HYMAI GLI1 NDUFAF4 NSDHL ORC4 MUSK DHCR7 PLK4 NUBPL NDUFB10 TCTN3 WDR4 ZMPSTE24 PSPH CTDP1 IGF1 DLL3 ERCC4 FGF8 GCK CDKN1C CTU2 DISP1 FGFR3 HSD11B2 PAH CENPE OTUD6B WDR73 PARN SOX4 NDUFAF5 DYNC2LI1 CENPE TBCE ATP6V1E1 GLI3 PLAGL1 FANCF SDHA ASXL1 NDUFV2 FTO BRPF1 YY1 LARS2 KLF11 PDX1 HOXD13 IGF1 ALX4 NDUFA11 CEP152 BLK ATP5F1A ALDH18A1 PTDSS1 IFIH1 ALG8 HIRA TRIM37 CEP57 MLXIPL MCTP2 PUF60 DHCR24 CTBP1 DOK7 CHRND NDUFS2 BUB1B PDX1 PDE4D ALDH18A1 INSR CITED2 PSAT1 GLI2 SAMD9 TINF2 NPM1 TRAIP XPR1 CHRNG FAM20C ATP7A COG7 FANCI ARVCF B3GLCT FKTN SEC24C FANCG COG6 DNAJC21 RNF113A TRAPPC11 RIPPLY2 TSFM ATR FLI1 IGF2 JMJD1C PDE6D COMT SUFU LIFR ERCC2 TTC37 SOX11 RNU4ATAC SDHAF1 INSR TDGF1 CCNQ NUP88 HMGA2 TP53RK SMARCA4 ATP6V0A2 BUB1B PIGG FLNB PCDH12 BCS1L SLC20A2 ARID1A CORIN PIEZO2 HDAC6 KIF2A PSAT1 MPLKIP NDUFA10 JAG1 ITPA RECQL4 NDUFAF3 PIEZO2 DLL1 RNU4ATAC GATA4 ERCC2 ND2 ARCN1 FANCB RARB KMT2A RAD51 PDGFB LAGE3 NDUFS1 GP1BB SIX3 FANCD2 POLR3A SKIV2L OSGEP NODAL XRCC4 QRICH1 ND1 NDUFS4 NOS3 GATA6 TTC7A SKIV2L TBCE BRCA1 COQ9 PAX4 RTEL1 LETM1 CENPJ NDUFA6 WHCR INSR NDUFA6 ASXL1 AARS1 XRCC2 CDC6 ARID1B SLC25A24 NDUFB11 RIPK4 RAPSN NIPBL TOP3A ERCC5 DONSON LEMD3 FGFR1 NDUFS6 SEMA5A ABCC8 RERE PCGF2 COQ7 CENPJ HES7 NKX2-5 EVC2 BRCA2 NDUFB9 FANCL NDUFB3 MYORG LMNA RBM10 RREB1 STN1 SMARCC2 RNU4ATAC POLR3A GTF2E2 ESCO2 SIN3A PLAGL1 TIMMDC1 WRAP53 PSAT1 PLK4 BCS1L HDAC6 TINF2 ABCB7 FOXRED1 NEK9 DKC1 GLI3 GJA5 CKAP2L PLK4 ERCC1 LMNA GTPBP3 CEP290 HHAT TMEM126B CDC6 DONSON PHGDH NIN NDUFAF1 FLT1 KCNJ11 SMARCE1 WARS2 CDC45 GATA6 HYLS1 SIX2 NDUFAF2 ALG1 SFXN4 SLC25A13 RAD51C DNAJC19 ERCC6 BMPER MBTPS2 PRKAR1A DYRK1A SF3B4 WDR73 ERCC6 NDUFA1 DPF2 SMARCA4 NDUFB3 SON ERCC2 STRA6 RPL11 MYH3 ABCC8 INS GAS1 ABCC8 ATP6V0A2 TARS1 FANCB TMEM70 STOX1 RFWD3 STT3B TERT CKAP2L HYMAI CHRNG LFNG NOP10 CDT1 GBA SEC61A1 NHP2 PCNT ATRIP TBC1D20 IBA57 CDT1 TBX1 NEUROD1 ABCC8 ORC1 SMC3 FANCI PRPS1 SMARCE1 NSD2 PTPN11 PARN NBN RNF113A MAD2L2 FGFR1 ORC4 TMEM216 HYMAI USB1 TRAIP SMARCAL1 SETD5 TTC7A WDR4 FANCA PIK3R1 ABL1 FGFRL1 NDUFAF4 SLX4 ORC6 RPL10 PHGDH CHRNA1 TRIP13 B3GLCT ZFP57 TAPT1 ERCC5 COG5 PKLR ACD COQ4 CUL7 MKS1 POLA1 RNASEH2A WNT4 GCK OSGEP GLIS3 PYCR1 SMARCAL1 SMC1A ERCC1 MCM5 EMG1 GATA4 PALB2 PTCH1 GMNN ZFPM2 SMC1A ORC6 TALDO1 BUB3 ZFP57 TBCE KCNJ11 MESP2 FANCE FUT8 SDHD FANCM RFWD3 MUSK RAF1 KDM6A BRAF LIG4 BLM HDAC8 ELN TUBGCP4 PCNT PDSS2 NDUFV1 CLCN7 PDGFRB DKC1 STT3B COG1 POLE NCAPG2 FOXH1 FMR1 RAB18 H19 RBM10 VPS13B SMAD4 NODAL NDUFB11 UFD1 KANSL1 EIF2AK3 GDF1 TBX4 SMAD4 ADGRG6 FIG4 TFAP2A KCNJ11 HNF1A NUP107 IGHMBP2 STAT3 PARN FLVCR2 ATP7A IGF1R GPKOW ACD PRKDC OTUD6B DHDDS TTC37 IGF1R NSD2 NIN WASHC5 PDX1 SOX11 TERC INS NDUFS7 ATP6V1A BUB1 CUL7 MCM4 ESCO2 TAF1 CTC1 PPP1R15B PEX5 SRCAP PCNT EXOSC9 RTTN CRKL CPLX1 ZIC2 TMEM70 ARL6IP6 NDE1 SLC25A24 TPRKB RNU4ATAC POLA1 NKX2-6 NSUN2 SMARCB1 TFAM XYLT1 CDCA7 ESCO2 NELFA ZMPSTE24 RFX6 FBN1 PDX1 SIN3A NDUFAF5 ERCC3 EVC MYOD1 SLC26A2 CDK10 RPS19 SC5D BRCA2 SLC35A2 TFAP2A NDUFS3 PDE4D DHCR7 TBCE SHH SMC1A TCTN3 KMT2A CEL NDUFS8 INS PLOD3 TINF2 WNT7A RAD21 GTF2E2 DNAJC19 KLHL7 UBR1 ZNF335 AFF2 GATA6 SMARCB1 KCNJ11 MAPK1 KIF5C CNOT1 GATA5 SNRPB BLM RAB3GAP1 HNF4A OBSL1 HADH TBX6 PNPT1 TGDS ARID2 KIF14 PEX2 BRIP1 TINF2 RAB3GAP2 TUBGCP6 SDHB ATR APPL1 DKC1 TUFM BCAP31 NUP133 ND3 SEMA3E UNC80 ATP6V0A2 FANCC BCR CHD7 CTNND2 BRIP1 FANCL SMARCA2 UQCC2 GFM1 TBX1 CDKN1C ERCC8 CEP57 RB1 SEC24D CCDC8 TBX1 P4HB POLE DDX11 UBE2T RTEL1 TERT IARS1
Preeclampsia
Genes 18
F5 HELLPAR SLC25A20 CORIN PPARG CFI NOS3 DHPS HBA1 CFH STOX1 CYP11B1 LBR CD46 EP300 HBA2 ADGRG6 CYP11B2
Toxemia of pregnancy
Genes 21
PPARG LMNA F5 NR3C2 HELLPAR SLC25A20 CORIN PPARG CFI NOS3 DHPS HBA1 CFH STOX1 CYP11B1 LBR CD46 EP300 HBA2 ADGRG6 CYP11B2